What is Abbott Lingo?

Abbott Lingo: adaptive-algorithmic glucose biometric archetype

Abbott Lingo is an FDA-cleared adaptive-algorithmic glucose biometric for non-diabetic consumers from Abbott. Per DEPLOY's biometric cluster framework, Lingo anchors the adaptive-algorithmic glucose biometric archetype within the biometric cluster's glucose-cell, paired with Dexcom Stelo's generative AI substance to document the within-cell AI-substance gradient.

---

FDA 510(k) K233655 May 2024 on FreeStyle Libre 14-day platform

Per Agent A Wave 3 biometric ingest, Abbott Lingo holds FDA 510(k) K233655 (May 2024): cleared on Abbott's FreeStyle Libre 14-day glucose monitoring platform. The K233655 clearance scope is for non-diabetic glucose monitoring: adults 18+ NOT on insulin.

Per cap-flag-as-trust-signal, the K233655 clearance scope precision matters editorially: the non-diabetic + 18+ + NOT-on-insulin scope is structurally distinct from diabetic-glucose-monitoring clearance scope (e.g., Dexcom G7 cleared for diabetics on insulin). The K233655 indication-specific framing is the load-bearing primary-source verification anchor.

---

CAP-FLAG IMPORTANCE: adults 18+ NOT on insulin (distinct from Dexcom G7)

Per Agent A Wave 3 biometric ingest, CAP-FLAG IMPORTANCE: Lingo is cleared for adults 18+ NOT on insulin; this is distinct from Dexcom G7 which is for diabetics on insulin. Per cap-flag-as-trust-signal, the indication-distinction matters editorially at the FDA-clearance verification layer:

• Abbott Lingo (K233655): adults 18+ NOT on insulin; non-diabetic consumer glucose monitoring; lifestyle + metabolic awareness use case.
• Dexcom G7: diabetics on insulin; diabetic glucose management; clinical insulin-dosing use case.

Per DEPLOY's framework, the indication distinction is editorial signal at the consumer-vs-clinical glucose monitoring layer: trade-press coverage that frames Lingo at diabetic glucose monitoring scope operates outside Agent A primary-source-anchored verification. The non-diabetic-consumer indication is the load-bearing verified scope.

---

~$54/2wk price point

Per Agent A Wave 3 biometric ingest + Agent B glucose pair /price ship, Abbott Lingo operates at ~$54 per 2-week sensor retail price point. The 14-day sensor lifecycle + sub-$60 price-per-cycle positions Lingo at the entry-tier consumer glucose monitoring layer.

Per DEPLOY's framework, the consumer-price-point framing is editorial signal at the biometric cluster's consumer-accessibility layer: the ~$54/2wk price point makes Lingo accessible at lifestyle + metabolic awareness tier (distinct from clinical diabetic CGM reimbursement-driven pricing).

---

AI substance: Lingo Count adaptive-algorithmic + rule-based (NOT generative)

Per Agent A Wave 3 biometric ingest, Abbott Lingo's AI substance is 'Lingo Count' adaptive-algorithmic recommendations + rule-based integration. The Lingo Count system operates at adaptive-algorithmic + rule-based AI substance tier, NOT generative AI.

Per DEPLOY's framework, the AI-substance type matters editorially at the within-cell AI-substance gradient layer: Lingo Count adaptive-algorithmic + rule-based is structurally distinct from Dexcom Stelo's Vertex AI + Gemini Weekly Insights generative AI substance. The within-cell gradient (same product category + same FDA clearance posture + diametrically opposite AI-substance tier) is the canonical AI-substance-gradient editorial throughline at the glucose-cell layer of the biometric cluster.

---

CAP-FLAG: Lingo Live is human nutritionists, NOT AI coach

Per Agent A Wave 3 biometric ingest, CAP-FLAG: 'Lingo Live' is human nutritionists, NOT AI coach. Per cap-flag-as-trust-signal, this is a critical cap-flag against common aggregator confusion:

• Lingo Count: adaptive-algorithmic + rule-based AI integration; in-app recommendations.
• Lingo Live: human nutritionists; live consultation service; NOT AI coach.

Per DEPLOY's framework, trade-press coverage that frames "Lingo Live" as Abbott's AI nutritionist coach operates outside Agent A primary-source-anchored verification. The human-vs-AI distinction is editorial signal at the marketing-claim verification layer: Lingo Live is a human-service feature, NOT an AI-substance feature.

---

Within-cell AI-substance gradient: Lingo adaptive-algorithmic vs Stelo generative

Per the biometric cluster framework, the within-cell AI-substance gradient is documented across the glucose pair:

• Dexcom Stelo: same product category (non-diabetic consumer CGM); same FDA clearance posture; AI substance = Vertex AI + Gemini Weekly Insights generative AI.
• Abbott Lingo: same product category; same FDA clearance posture; AI substance = Lingo Count adaptive-algorithmic + rule-based.

Per DEPLOY's framework, the within-cell AI-substance gradient is the canonical glucose-cell editorial throughline: same product category + same FDA clearance posture + diametrically opposite AI-substance tier. The gradient documents the AI-substance verification layer within the biometric cluster at form-factor-cell granularity.

---

Cohort positioning: adaptive-algorithmic glucose biometric archetype

Per the biometric cluster framework, Abbott Lingo anchors:

• Adaptive-algorithmic glucose biometric archetype: Lingo Count adaptive-algorithmic + rule-based AI integration; distinct from Stelo generative AI substance tier.
• Non-diabetic consumer indication: adults 18+ NOT on insulin; structurally distinct from Dexcom G7 diabetic + insulin indication.
• FreeStyle Libre 14-day platform: FDA 510(k) K233655 May 2024 on Abbott's existing CGM platform.
• ~$54/2wk consumer price: entry-tier consumer glucose monitoring layer.

Contrast with cohort:

• Dexcom Stelo: paired glucose-cell entry; same product category; generative AI substance (Vertex AI + Gemini Weekly Insights).
• RingConn (Gen 2 / Gen 3): ring cohort; subscription-free; AHI not FDA-cleared.
• Ultrahuman Ring (Air / Pro): ring cohort; market-access-redesigned.
• Happy Ring: ring cohort; FDA-cleared + service-gated.
• Whoop: band cohort; subscription-only.

For the canonical biometric cluster context, see the biometric cluster. For the paired glucose-cell entry with generative AI substance, see what is Stelo. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Abbott Lingo: verified-vs-claimed at within-entity granularity (within-Abbott OTC Lingo vs prescription Libre product-family verification scope; AI-augmented vs AI-primary boundary) + the 9-tier source-quality rubric (FDA OTC clearance + Abbott SEC source classification).